肠道菌群及其代谢物与肌少症的因果关联:孟德尔随机化研究
本研究采用连锁不平衡得分回归和两样本孟德尔随机化方法,以大规模全基因组关联研究的单核苷酸多态性为工具变量,检验肠道菌群及其代谢物与肌少症的因果关联。结果显示特定菌属丰度与步行速度、四肢瘦体重和握力相关,并识别出21种可能与肌少症风险相关的肠道菌群衍生代谢物。结论提示肠道菌群及代谢物可能是肌少症的潜在风险因素。
要点
- 多孔菌科、理研菌科等菌属丰度与步行速度相关。
- 12种肠道菌与四肢瘦体重提示相关,5种菌与握力提示相关。
- 识别出21种肠道菌群衍生代谢物可能与肌少症风险相关。
核心结论
- 肠道菌群及其衍生代谢物与肌少症存在因果关联,可能为潜在风险因素及治疗靶点。
研究设计与样本
- 采用连锁不平衡得分回归和两样本孟德尔随机化方法,工具变量为大规模全基因组关联研究来源的单核苷酸多态性。
- 孟德尔随机化分析后进行了敏感性分析以增强结果的稳健性和可信度。
主要发现
- 多孔菌科、理研菌科、Terrisporobacter和Victivallis的丰度与步行速度相关。
- 12种肠道菌与四肢瘦体重提示相关。
- 链球菌科、Intestinibacter、Paraprevotella、Ruminococcaceae UCG009和Sutterella与握力提示相关。
- 识别出21种肠道菌群衍生代谢物可能与肌少症风险相关。
临床怎么用
- 肠道菌群及代谢物可作为肌少症风险评估的潜在关注方向。
- 研究结果为开发针对肠道菌群的新型治疗靶点提供了线索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gut microbiota imbalance and sarcopenia are frequently observed in older adults. Gut microbiota and their metabolites are considered risk factors contributing to the heightened risk of sarcopenia, but whether these associations are causal remains unclear. METHODS: We conducted linkage disequilibrium score regression and 2-sample Mendelian randomization (MR) methods with single-nucleotide polymorphisms sourced from large-scale genome-wide association studies as instrumental variables to examine the causal associations linking gut microbiota with their metabolites to the sarcopenia. Following the MR analysis, subsequent sensitivity analyses were conducted to reinforce the robustness and credibility of the obtained results. RESULTS: MR analysis yielded compelling evidence demonstrating the correlation between genetically predicted gut microbiota and metabolites and the risk of sarcopenia. The abundance of Porphyromonadaceae, Rikenellaceae, Terrisporobacter, and Victivallis was found to be associated with walking pace. Our study also found suggestive associations of 12 intestinal bacteria with appendicular lean mass, and of Streptococcaceae, Intestinibacter, Paraprevotella, Ruminococcaceae UCG009, and Sutterella with grip strength. Specifically, we identified 21 gut microbiota-derived metabolites that may be associated with the risk of sarcopenia. CONCLUSIONS: Utilizing a 2-sample MR approach, our study elucidates the causal interplay among gut microbiota, gut microbiota-derived metabolites, and the occurrence of sarcopenia. These findings suggest that gut microbiota and metabolites may represent a potential underlying risk factor for sarcopenia, and offer the promise of novel therapeutic focal points.
引用
- Zhang X, Yang G, Jiang S, et al. Causal Relationship Between Gut Microbiota, Metabolites, and Sarcopenia: A Mendelian Randomization Study. J Gerontol A Biol Sci Med Sci. 2024. PMID: 38995073. doi:10.1093/gerona/glae173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。